NYSE:MTNB
Matinas Biopharma Holdings Inc Stock News
$0.190
-0.0020 (-1.04%)
At Close: Apr 18, 2024
Matinas: Learning From Amarin's Mistakes
08:05pm, Wednesday, 06'th Jan 2021
Matinas has an OM3 drug that has demonstrated a superior profile to Amarin's Vascepa. It has a platform and, unlike Amarin, a diverse pipeline.
Why Matinas BioPharma Holdings Shot Almost 28% Higher Today
07:35pm, Monday, 04'th Jan 2021
The proposed brand name for its leading pipeline drug got an important nod.
BEDMINSTER, N.J., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on developing next generation therapeutics to
Matinas BioPharma Files Preliminary Proxy for Special Meeting of Stockholders
06:30am, Monday, 07'th Dec 2020
- Special Meeting of Stockholders Scheduled for January 26, 2021 Seeking Authorization to Potentially Effectuate a Discretionary Reverse Stock Split Prior to January 26, 2022 -
Matinas BioPharma Appoints Hui Liu, Ph.D., M.B.A. as Chief Technology Officer
07:00am, Tuesday, 01'st Dec 2020
– Dr. Liu brings more than 20 years of expertise in pharmaceutical development, formulation, and CMC, with specific focus on lipid-based delivery of complex molecules – – Dr. Liu brings more tha
BEDMINSTER, N.J., Nov. 20, 2020 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on developing next generation therapeutics to
Matinas BioPharma to Participate in Annual Piper Sandler Healthcare Conference
04:15pm, Thursday, 19'th Nov 2020
BEDMINSTER, N.J., Nov. 19, 2020 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on developing next generation therapeutics to
Matinas BioPharma Holdings, Inc. (MTNB) CEO Jerry Jabbour on Q3 2020 Results - Earnings Call Transcript
09:10pm, Friday, 06'th Nov 2020
Matinas BioPharma Holdings, Inc. (MTNB) CEO Jerry Jabbour on Q3 2020 Results - Earnings Call Transcript
Matinas BioPharma Reports Third Quarter 2020 Financial Results and Operational Highlights
07:00am, Friday, 06'th Nov 2020
EnACT study of MAT2203 in cryptococcal meningitis received unanimous D ata and Safety Monitoring Board (DSMB) recommendation to pro ceed into second patient cohort
BeiGene COVID-19 Deal And Other News: The Good, Bad And Ugly Of Biopharma
04:22am, Sunday, 30'th Aug 2020
BeiGene signs deal with Singlomics for neutralizing COVID-19 antibodies. UroGen flunks Phase 2 RTGel combo study.
Matinas Biopharma Holdings, Inc. (MTNB) Reports Q2 Loss, Lags Revenue Estimates
09:35pm, Monday, 10'th Aug 2020
Matinas Biopharma Holdings, Inc. (MTNB) delivered earnings and revenue surprises of 0.00% and -100.00%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for
Matinas BioPharma Reports Second Quarter 2020 Financial Results and Operational Highlights
08:05pm, Monday, 10'th Aug 2020
– ENHANCE-IT study of MAT9001 against Vascepa® expected to be fully enrolled in August 2020; topline data anticipated Q1 2021 – – EnACT study of MAT2203 in cryptococcal meningitis resumed enro
The Week Ahead In Biotech: Bausch Health, Fennec Pharma FDA Decisions And Smid-cap Earnings
12:00am, Sunday, 09'th Aug 2020
Biotech stocks advanced in the week ended Aug. 7, buoyed by multiple catalysts. Aside from the broader market strength, mostly positive earnings and continuing coronavirus...
Earnings Preview for Matinas BioPharma Hldgs
03:00pm, Friday, 07'th Aug 2020
On Monday, August 10, Matinas BioPharma Hldgs (AMEX: MTNB) will release its latest earnings report. Benzinga's outlook for Matinas BioPharma Hldgs is included in the following report.Earnings and Reve
LD Micro--Announces Preliminary List of Presenters for the LD-500.
08:21pm, Wednesday, 05'th Aug 2020
LOS ANGELES, CA / ACCESSWIRE / August 5, 2020 / LD Micro today announced the initial list of companies slated to present at the upcoming LD 500, taking place September 1st-4th, 2020, exclusively onlin
